Literature DB >> 27406352

I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.

Lisa A Carey1, Eric P Winer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27406352     DOI： 10.1056/NEJMe1603691

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.

Authors:  Sawsan Rashdan; David E Gerber
Journal:  Ann Transl Med       Date:  2016-12

Review 2.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

3.  Immunotherapy is different: Implications for vaccine clinical trial design.

Authors:  Richard Simon
Journal:  Hum Vaccin Immunother       Date:  2017-05-12       Impact factor: 3.452

4.  Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.

Authors:  Rebecca S Slack Tidwell; S Andrew Peng; Minxing Chen; Diane D Liu; Ying Yuan; J Jack Lee
Journal:  Clin Trials       Date:  2019-08-26       Impact factor: 2.486

5.  Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.

Authors:  Lisi M Dredze; Michael Friger; Samuel Ariad; Michael Koretz; Bertha Delgado; Ruthy Shaco-Levy; Margarita Tokar; Michael Bayme; Ravit Agassi; Maia Rosenthal; Victor Dyomin; Olga Belochitski; Shai Libson; Tamar Mizrahi; David B Geffen
Journal:  Breast Cancer Res Treat       Date:  2022-04-22       Impact factor: 4.872

6.  Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.

Authors:  Lillian L Siu; S Percy Ivy; Erica L Dixon; Amy E Gravell; Steven A Reeves; Gary L Rosner
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

7.  Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.

Authors:  Laura M Spring; Geoffrey Fell; Andrea Arfe; Lorenzo Trippa; Aditya Bardia; Chandni Sharma; Rachel Greenup; Kerry L Reynolds; Barbara L Smith; Brian Alexander; Beverly Moy; Steven J Isakoff; Giovanni Parmigiani
Journal:  Clin Cancer Res       Date:  2020-02-11       Impact factor: 12.531

8.  Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset.

Authors:  Richard Ha; Christine Chin; Jenika Karcich; Michael Z Liu; Peter Chang; Simukayi Mutasa; Eduardo Pascual Van Sant; Ralph T Wynn; Eileen Connolly; Sachin Jambawalikar
Journal:  J Digit Imaging       Date:  2019-10       Impact factor: 4.056

9.  Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.

Authors:  Luca Gianni; Mauro Mansutti; Antonio Anton; Lourdes Calvo; Giancarlo Bisagni; Begoña Bermejo; Vladimir Semiglazov; Marc Thill; Jose Ignacio Chacon; Arlene Chan; Serafin Morales; Isabel Alvarez; Arrate Plazaola; Milvia Zambetti; Andrew D Redfern; Christian Dittrich; Rebecca Alexandra Dent; Domenico Magazzù; Raffaella De Fato; Pinuccia Valagussa; Ignacio Tusquets
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

Review 10.  PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.

Authors:  Geraldine O'Sullivan Coyne; Alice P Chen; Robert Meehan; James H Doroshow
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.